Business Context and Reporting Period
This Form 6-K filing by China SXT Pharmaceuticals, Inc. covers the month of May 2019, specifically reporting on an amendment to a Securities Purchase Agreement and the subsequent completion of a private placement transaction.
Key Financial Metrics
- Transaction Size: $15 million aggregate principal amount of Senior Convertible Notes ($10 million Series A; $5 million Series B).
- Consideration Received: $10 million in cash and a $5 million secured promissory note (Investor Note) from investors.
- Net Proceeds: Approximately $9 million after deducting commissions and offering expenses.
- Transaction Costs: $750,000 cash fee to the placement agent, $30,000 reimbursed expenses, $25,000 reimbursed legal fees for the agent, and approximately $75,000 reimbursed legal fees for the lead investor.
- Warrants Issued: Warrants to purchase shares equal to 50% of shares issuable upon conversion of the Notes, plus a placement agent warrant for 178,997 shares.
Material Changes
The primary material change involves an amendment to the original April 16, 2019, Securities Purchase Agreement. The original agreement required a Share Pledge Agreement where a third party (Feng Zhou Management Limited) would pledge 4 million ordinary shares as security. Under the May 2, 2019, Amendment, the Share Pledge Agreement was removed. Instead, the Company agreed to pre-deliver 4 million ordinary shares (Pre-Delivery Shares) to the investors as security. These shares are restricted and must be returned for cancellation if the Notes are converted or redeemed and the shares are not used to satisfy the conversion.
Outlook, Risks, and Unusual Items
- Liquidity Impact: The transaction provides immediate liquidity through $10 million in cash and a $5 million note receivable from investors.
- Securities Restrictions: The Notes, Warrants, and Pre-Delivery Shares are not listed on any national securities exchange, and no trading market is expected to develop for them.
- Registration Rights: The Company has agreed to register for resale the ordinary shares issuable upon conversion of the Notes and exercise of the Warrants.
- Netting Agreements: Master Netting Agreements were executed to clarify rights to offset obligations between the Company and investors under various transaction documents.
Investor Verification Checklist
- Verify the terms of the $5 million Investor Note payable by investors to the Company, including repayment conditions and security.
- Confirm the status of the 4 million Pre-Delivery Shares and the conditions under which they must be returned to the Company.
- Review the Registration Rights Agreement to understand the timeline and obligations for registering the resale of shares.
- Assess the impact of the $15 million convertible debt on future dilution and interest obligations.
- Examine the "Investor Note" structure to ensure it is a valid asset on the Company's balance sheet and not a liability.